U.S. Communications Stock News

Freedom Capital’s new coverage of Gambling.com Group (GAMB), focused on sports data services and revised revenue guidance, has pushed the stock into the spotlight for investors tracking online gambling and data driven revenue models. See our latest analysis for Gambling.com Group. The recent initiation of coverage comes at a time when Gambling.com Group’s 90 day share price return of 31.66% decline and 1 year total shareholder return of 62.46% decline signal fading momentum, even as sports...

In recent days, Sprinklr has attracted increasing investor attention for its AI-driven Unified Customer Experience Management platform, which helps enterprises manage communication across multiple channels and internal teams. This renewed interest highlights how Sprinklr’s AI capabilities are becoming more relevant for companies pursuing digital transformation and integrated customer engagement. Next, we’ll examine how Sprinklr’s growing emphasis on AI-powered customer experience tools could...

Donaldson Company (NYSE:DCI) has had a great run on the share market with its stock up by a significant 17% over the...

Zentalis Pharmaceuticals recently reported completing Part 2a enrollment in its DENALI trial, aligning with the FDA on the Phase 3 ASPENOVA design for azenosertib and outlining expectations for dose confirmation and topline data by the end of 2026. Alongside these pipeline updates, a 10 percent owner, Walters Group, bought about 6,459,973 shares for roughly US$7.70 million, underscoring insider confidence as the company also refocuses azenosertib away from uterine serous carcinoma and toward...

Key Insights Given the large stake in the stock by institutions, Solventum's stock price might be vulnerable to their...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...

We wouldn't blame Nuvalent, Inc. ( NASDAQ:NUVL ) shareholders if they were a little worried about the fact that James...

Despite an already strong run, Binah Capital Group, Inc. ( NASDAQ:BCG ) shares have been powering on, with a gain of...

We'd be surprised if Relay Therapeutics, Inc. ( NASDAQ:RLAY ) shareholders haven't noticed that the CEO, President...

Some Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders may be a little concerned to see that the Co-Founder, Ryan...

Key Insights Given the large stake in the stock by institutions, Fractyl Health's stock price might be vulnerable to...

What Costamare’s Latest Dividend Move Signals for Investors Costamare (CMRE) recently reaffirmed its income profile by declaring a quarterly dividend of $0.115 per common share, along with scheduled payments on its Series B, C, and D preferred shares. For common shareholders, the $0.115 dividend relates to the quarter ended December 31, 2025 and is payable on February 5, 2026 to investors on record as of January 20, 2026. Preferred investors are set to receive $0.476563 per Series B share,...

Why 3D Systems Is Back on Investor Radar 3D Systems (DDD) is drawing fresh attention after expanding its U.S. facilities, securing 510(k) clearance for its VSP Orthopedics platform, and advancing defense work supported by the National Defense Authorization Act. See our latest analysis for 3D Systems. These updates have arrived during a volatile stretch, with a 7 day share price return of 25.95% and a 30 day gain of 22.63% following a 90 day decline of 25.08%. At the same time, the 1 year...

Potential Dorian LPG Ltd. ( NYSE:LPG ) shareholders may wish to note that the Chairman of the Board, John Hadjipateras...

Pomerantz LLP recently announced it is investigating potential claims on behalf of investors of Village Farms International, Inc., inviting affected shareholders to contact the firm for more information. This type of investor-focused legal review can intensify scrutiny of Village Farms’ governance and disclosures, adding a new layer of risk perception around the company. We’ll now examine how this investor legal investigation could influence Village Farms International’s cannabis-focused...

In recent updates, Celldex Therapeutics reported progression of its antibody pipeline, including global Phase 3 trials for barzolvolimab in chronic urticarias and early-stage data for bispecific antibody CDX-622. A key insight for investors is Celldex’s cash runway reportedly extending through 2027, supporting continued development of these late- and mid-stage programs. Next, we’ll explore how this pipeline momentum, particularly the Phase 3 barzolvolimab program, shapes Celldex...

With a price-to-earnings (or "P/E") ratio of 27.9x Veralto Corporation ( NYSE:VLTO ) may be sending bearish signals at...

Atmus Filtration Technologies Inc. ( NYSE:ATMU ), might not be a large cap stock, but it received a lot of attention...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights The considerable ownership by individual investors in GrabAGun Digital Holdings indicates that they...

Despite an already strong run, GSI Technology, Inc. ( NASDAQ:GSIT ) shares have been powering on, with a gain of 37% in...

While Formula One Group ( NASDAQ:FWON.K ) shareholders are probably generally happy, the stock hasn't had particularly...

You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...